Darolutamide N-((S)-1-(3-(3-Chloro-4-cyanophenyl)-1H-pyrazol-1-yl)-propan-2-yl)-5-(1-hydroxyethyl)-1H-pyrazole-3-carboxamide N-((S)- 1 -(3-(3-chloro-4-cyanophenyl)- lH-pyrazol- 1 -yl)-propan-2-yl)-5-(l-hydroxyethyl)-lH-pyrazole-3-carboxamide MF C19H19ClN6O2 MW 398.846 BAY 1841788; ODM-201 даролутамид [Russian] [INN] دارولوتاميد [Arabic] [INN] 达罗他胺 [Chinese] [INN] ダロルタミド JAPANESE ダロルタミド Darolutamide C19H19ClN6O2 : 398.85 [1297538-32-9] 1H-Pyrazole-3-carboxamide, N-[(1S)-2-[3-(3-chloro-4-cyanophenyl)-1H-pyrazol-1-yl]-1-methylethyl]-5-(1-hydroxyethyl)- BAY-1841788 N-{(2S)-1-[3-(3-Chlor-4-cyanphenyl)-1H-pyrazol-1-yl]-2-propanyl}-5-(1-hydroxyethyl)-1H-pyrazol-3-carboxamid N-{(2S)-1-[3-(3-Chloro-4-cyanophenyl)-1H-pyrazol-1-yl]-2-propanyl}-5-(1-hydroxyethyl)-1H-pyrazole-3-carboxamide N-{(2S)-1-[3-(3-Chloro-4-cyanophényl)-1H-pyrazol-1-yl]-2-propanyl}-5-(1-hydroxyéthyl)-1H-pyrazole-3-carboxamide ODM-201 1297538-32-9  CAS UNII:X05U0N2RCO phase 3 for Hormone refractory prostate cancer; Hormone dependent prostate cancer Orion and licensee Bayer are codeveloping darolutamide (ODM-201, BAY-1841788), an androgen receptor antagonist, for the … Continue reading DAROLUTAMIDE даролутамид , دارولوتاميد , 达罗他胺 , ダロルタミド